Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma
Status:
Completed
Trial end date:
2020-07-15
Target enrollment:
Participant gender:
Summary
This is a single-arm phase I/Ib study of crenolanib combined with ramucirumab/paclitaxel as
second line therapy for patients with advanced/metastatic adenocarcinoma of the esophagus,
GEJ or stomach. Patients will be enrolled in two phases; dose escalation phase and dose
expansion phase.